Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blin...
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
About this item
Full title
Author / Creator
Confavreux, Christian, Prof , O'Connor, Paul, Prof , Comi, Giancarlo, Prof , Freedman, Mark S, Prof , Miller, Aaron E, Prof , Olsson, Tomas P, Prof , Wolinsky, Jerry S, Prof , Bagulho, Teresa, MD , Delhay, Jean-Luc, MD , Dukovic, Deborah, MS , Truffinet, Philippe, MD , Kappos, Ludwig, Prof , for the TOWER Trial Group and TOWER Trial Group
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. We aimed to provide further evidence for the safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis. Methods This international, randomised, double-blind, placebo-controlled...
Alternative Titles
Full title
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors, Artists and Contributors
Author / Creator
O'Connor, Paul, Prof
Comi, Giancarlo, Prof
Freedman, Mark S, Prof
Miller, Aaron E, Prof
Olsson, Tomas P, Prof
Wolinsky, Jerry S, Prof
Bagulho, Teresa, MD
Delhay, Jean-Luc, MD
Dukovic, Deborah, MS
Truffinet, Philippe, MD
Kappos, Ludwig, Prof
for the TOWER Trial Group
TOWER Trial Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_524113
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_524113
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(13)70308-9
